E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The two main categories of inflammatory bowel disease (IBD) are ulcerative colitis and Crohn’s disease. Crohn’s disease is characterized by recurring episodes of suppurative inflammation of any part of the bowel, from the mouth to the anus. This can result in strictures, microperforations, and fistulas. Crohn’s patients typically expetience fever, weight loss, stomatitis, perianal fistulae and/or fissures, arthritis, and erythema nodosum. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to evaluate the safety and efficacy of AST-120 in the treatment of mild to moderately severe fistulizing Crohn’s disease. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
In the United Kingdom, patients who respond positively to treatment (as defined per protocol) at either Week 8 or Week 16, and if deemed appropriate by their physician, will be offered access to open-label AST-120 beginning at follow-up Week 24 or relapse, whichever occurs sooner. Access to open-label AST-120 will continue for a period up to 6 months as long as, in the opinion of the investigator, the patient continues to experience treatment benefit. During open label treatment, the investigator will see the patient on a schedule commensurate with the standard of care for their practice/institution. The investigator will perform clinical evaluations commensurate with the standard of care for their practice/institution. No efficacy data will be collected during this period. Investigators will be provided with standard forms for recording safety data. Safety data from this open label treatment will be analyzed separately. |
|
E.3 | Principal inclusion criteria |
18 to 70 years of age Body Weight: (≥40 kg) Documented diagnosis of Crohn’s disease, including patients with documented diagnosis of ileitis, colitis, or ileocolitis Presence of at least one draining perianal fistula. Patients with enterocutaneous fistulas can be included if they have ≥ 1 draining perianal fistula. Women with rectovaginal fistulas are included if they have ≥ 1 draining perianal fistula. Crohn’s Disease Activity Index (CDAI) score < 400 Platelet count (thrombocytes) ≥100,000/µL Able and willing to comply with all protocol procedures |
|
E.4 | Principal exclusion criteria |
Patients previously treated with infliximab for fistulas cuased by Crohn's disease and who did not respond to infliximab therapy. Infliximab therapy within 3 months prior to enrollment in the study Presence of symptomatic strictures or suggestion of significant clinical obstruction Patients with setons are excluded unless setons are removed at least 48 hours prior to study entry Presence of entero-entero, recto-vesicular, entero-vesicular fistulas The patient is unable to stay on a stable dose of concomitant Crohn’s disease medication(s) for at least 10 weeks in the opinion of the investigator Currently symptomatic untreated diarrhea due to conditions other than mild to moderately active Crohn’s disease (e.g. bacterial or parasitic gastroenteritis, bile salt diarrhea, etc.) Severe diarrhea defined by > 10 liquid bowel movements per day Other local manifestations of mild to moderately active Crohn’s disease such as abscesses, or other disease manifestations for which surgery might be indicated, or which might preclude utilization of a CDAI to assess response to therapy (e.g. short bowel syndrome) Receiving Total Parenteral Nutrition (TPN) as the sole source of nutrition within 3 weeks of Screen Hemoglobin < 8.5 g/dL (females) or hemoglobin < 10 g/dL (males) at Screen Women who are pregnant, breast feeding, or planning to become pregnant during the study Other major physical or major psychiatric illness within the last 6 months that in the opinion of the investigator would affect the patient's ability to complete the trial Uncontrolled systemic disease Patients undergoing chemotherapy for the treatment of cancer |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn’s disease with fistulas defined by: A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8.
The primary safety endpoint is adverse events (AEs) deemed possibly, probably, or definitely related to treatment with investigational product during 8 weeks of treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
A patient is defined as having completed study treatment if he/she has received product and is followed for safety through the last on-site visit of the first randomized treatment course (Visit 3, Week 8). Patients who fail the first course of treatment will have the option to get the alternative blinded treatment for one treatment course (8 weeks). Study completion is reached at relapse or Week 24. No investigational product will be administered during the follow-up period. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |